Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

39.84
+0.24000.61%
Volume:1.97M
Turnover:78.75M
Market Cap:10.98B
PE:22.64
High:40.26
Open:39.25
Low:39.11
Close:39.60
Loading ...

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks
·
02 May

Press Release: Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Dow Jones
·
30 Apr

U.S. RESEARCH ROUNDUP-Domino's Pizza, Prologis, Springworks Therapeutics

Reuters
·
29 Apr

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)

TIPRANKS
·
28 Apr

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Zacks
·
26 Apr

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks
·
24 Apr

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks
·
22 Apr

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks
·
16 Apr

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks
·
08 Apr

Exelixis (EXEL) Gets a Buy from RBC Capital

TIPRANKS
·
05 Apr

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks
·
03 Apr

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Insider Monkey
·
02 Apr

Exelixis Launches Special Equity Award Program

TIPRANKS
·
01 Apr

Guggenheim Remains a Buy on Exelixis (EXEL)

TIPRANKS
·
30 Mar

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Zacks
·
28 Mar

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)

TIPRANKS
·
27 Mar

Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Mar

Exelixis to present positive preclinical data across pipeline portfolio at AACR

TipRanks
·
27 Mar

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Zacks
·
27 Mar

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

Reuters
·
27 Mar